Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $50 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $50 price target.

byBenzinga Newsdesk

February 15, 2023

1 minute read

HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $50 price target.

Analog Devices Unleashes $2.5B Accelerated Share Repurchase, Raises Q4 Revenue Outlook

By Anusuya Lahiri

Today, 10:57 AM

Analog Devices Inc (NASDAQ:ADI) forged multiple accelerated share repurchase (ASR) agreements to repurchase up to $2.5 billion of shares. The company…

ADI

Goldman Sachs Downgrades L3Harris Technologies to Sell, Announces $207 Price Target

By vishwanath@benzinga.com

Today, 10:57 AM

Goldman Sachs analyst Noah Poponak downgrades L3Harris Technologies (NYSE:LHX) from Neutral to Sell and announces $207 price target.

LHX

MKM Partners Maintains Buy on World Wrestling Enter, Raises Price Target to $79

By Benzinga Newsdesk

Today, 10:57 AM

MKM Partners analyst Eric Handler maintains World Wrestling Enter (NYSE:WWE) with a Buy and raises the price target from $70 to $79.

WWE

Analyst Ratings

What 12 Analyst Ratings Have To Say About American Express

By Benzinga Insights

Today, 10:57 AM

American Express (NYSE:AXP) has observed the following analyst ratings within the last quarter:

AXP

HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $50 Price Target

Related Posts

Analog Devices Unleashes $2.5B Accelerated Share Repurchase, Raises Q4 Revenue Outlook

Goldman Sachs Downgrades L3Harris Technologies to Sell, Announces $207 Price Target

MKM Partners Maintains Buy on World Wrestling Enter, Raises Price Target to $79

What 12 Analyst Ratings Have To Say About American Express